EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis

Wei Sun, Shaohui Zhuang, Minghua Cheng, Zeting Qiu

Frontiers in Oncology · 30.03.2023 · 13

DOI: 10.3389/fonc.2023.1134744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 30.03.2023. Verfasst von Wei Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Opioids are widely used for patients with solid tumors during surgery and for cancer pain relief. We conducted a pan-cancer genomic analysis to investigate the prognostic features of Mu opioid receptor ( MOR ) mRNA expression across 18 primary solid cancers.

Methods

All the data of cancer with MOR mRNA were retrieved from cBioPortal for Cancer Genomics. Logistic regression was used to determine the associations between MOR mRNA expression and clinicopathological features. Log-rank test and Cox regression was used for survival analysis. Subgroup analysis and propensity score matching were also carried out.

Results

7,274 patients, including 1,112 patients with positive MOR mRNA expression, were included for data analyses. Positive MOR mRNA expression was associated with more advanced stage of T (adjusted Odds ratio [OR], 1.176; 95% confidence interval [CI], 1.022-1.354; P =0.024), M (adjusted OR, 1.548; 95% CI, 1.095-2.189; P =0.013) except N (adjusted OR, 1.145; 95% CI, 0.975-1.346; P =0.101), and worse prognosis for overall survival (Hazard ratio [HR] 1.347, 95% CI 1.200-1.512, P <0.001), progression-free survival (HR 1.359, 95% CI 1.220-1.513, P <0.001), disease-free survival (HR 1.269, 95% CI 1.016-1.585, P <0.001) and disease-specific survival (HR 1.474, 95% CI 1.284-1.693, P <0.001). Patients with positive MOR mRNA expression tended to be classified as tumor microenvironment immune types II, representing low PD-L1 and low CD8A expression.

Conclusion

MOR mRNA overexpression is associated with poor prognosis and poor response to PD-L1 therapy.

Schlagwörter

Stichwörter der Autor:innen

Mu opioid receptoropioidpan-cancer analysisprognostic featuressolid cancer

Autor:innen und Institutionen

  • Department of Anesthesiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.

Zitieren

APA

Sun, W., Zhuang, S., Cheng, M., & Qiu, Z. (2023). Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1134744

Vancouver

Sun W, Zhuang S, Cheng M, Qiu Z. Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1134744

BibTeX
@article{Sun2023,
  author = {Sun, Wei and Zhuang, Shaohui and Cheng, Minghua and Qiu, Zeting},
  title = {Mu opioid receptor mRNA overexpression predicts poor prognosis among 18 common solid cancers: A pan-cancer analysis},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1134744}
}
Kostenlos starten →